Biogen
$222.82Change from previous close: −1.35%Absolute change: −$3.06
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $32.92B
- Enterprise value
- $39.99B
- P/E (trailing 12 months)
- 39.6
- Forward P/E
- 13.5
- PEG
- 2.33
- Price/book
- 1.75
- Price/sales
- 3.28
- EV/EBITDA
- 11.9
- EV/revenue
- 3.99
Profitability and growth
- Gross margin
- 78.3%
- Operating margin
- 25.1%
- Net margin
- 8.3%
- ROE
- 4.6%
- ROA
- 5.2%
- Revenue growth (year over year)
- 3.4%
- Earnings growth (year over year)
- -84.8%
Financial health
- Total cash
- $1.28B
- Total debt
- $8.36B
- Debt/equity
- 0.44
- Current ratio
- 1.87
- Quick ratio
- 0.94
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $238.18
- Median price target
- $240.00
- High price target
- $300.00
- Low price target
- $175.00
- Analysts with a price target
- 31
- Consensus
- Buy
- Forward EPS
- $16.54
- EPS estimate, current year
- $12.54
Shares and trading
- Beta
- 0.17
- Average volume
- 1.08M
- Shares outstanding
- 147.75M
- Float
- 147.22M
- Institutional ownership
- 99.5%
- Insider ownership
- 0.2%
- Short interest (% of float)
- 4.4%
- Short ratio (days)
- 8.07